Research Site
Evansville, Indiana, United States
NCT Number: NCT01943513
The primary objective of this study is to determine whether muscle atrophy induced by immobilization of the lower limb can be attenuated by BIIB023 in healthy male volunteers. The secondary objectives of this study in this study population are:
* To determine whether muscle weakness induced by immobilization of the lower limb can be attenuated by BIIB023 * To assess the effect of BIIB023 on the recovery of muscle mass and strength after immobilization * To assess the effect of BIIB023 on histological markers of muscle atrophy and regeneration * To assess the effect of BIIB023 on muscle bioenergetics based on oxidative metabolism recovery kinetics * To evaluate the safety and tolerability of BIIB023
Looking for future studies?
Notify Me18 year–35 year
Male
Interventional
Phase 1
Evansville, Indiana, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol-defined inclusion/exclusion criteria may apply.
Intravenous (IV) infusions
Other names: (anti-TWEAK [TNF-related Weak Inducer of Apoptosis] monoclonal antibody)
Matched placebo
Time frame: between Day 14 and Day 42
Time frame: between Day 14 and Day 42
Time frame: between Day 14 and Day 42
Time frame: between Day 14 and Day 42
Time frame: between Day 14, Day 21, and Day 42
Time frame: between Day 14, Day 21, and Day 42
Time frame: between Day 14 and Day 42
Time frame: Day 156
Biogen
Industry
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of Intravenous BIIB023 (Anti-TWEAK) on Lower Limb Muscle Mass and Strength During and After Knee-Joint Immobilization in Healthy Male Volunteers
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05814705
Healthy, Muscle Disuse Atrophy
Hamilton, Ontario, Canada
View Trial DetailsNCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial Details